|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
|
US5994391A
(en)
*
|
1994-09-13 |
1999-11-30 |
G.D. Searle And Company |
Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6107494A
(en)
*
|
1994-09-13 |
2000-08-22 |
G.D. Searle And Company |
Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
GB9423172D0
(en)
*
|
1994-11-17 |
1995-01-04 |
Wellcom Foundation The Limited |
Hypolipidemic benzothiazepines
|
|
GB9704208D0
(en)
*
|
1997-02-28 |
1997-04-16 |
Glaxo Group Ltd |
Chemical compounds
|
|
DE69815180T2
(de)
*
|
1997-03-14 |
2004-04-29 |
Aventis Pharma Deutschland Gmbh |
Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide
|
|
GB9800428D0
(en)
|
1998-01-10 |
1998-03-04 |
Glaxo Group Ltd |
Chemical compounds
|
|
US6462091B1
(en)
|
1998-12-23 |
2002-10-08 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
|
|
CZ20012341A3
(cs)
|
1998-12-23 |
2001-12-12 |
G. D. Searle Llc Corparate Patent Department |
Kombinace inhibitorů transferoního proteinu cholesterylesterů a derivátů kyseliny fibrové pro kardiovaskulární indikace
|
|
PL348508A1
(en)
|
1998-12-23 |
2002-05-20 |
Searle Llc |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
|
US6562860B1
(en)
|
1998-12-23 |
2003-05-13 |
G. D. Searle & Co. |
Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
|
|
ES2200588T3
(es)
|
1998-12-23 |
2004-03-01 |
G.D. Searle Llc |
Combinacion de inhibidores del transporte de oxido biliar ileal y de derivados de acido fibrico para indicaciones cardiovasculares.
|
|
US6489366B1
(en)
|
1998-12-23 |
2002-12-03 |
G. D. Searle, Llc |
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
|
|
ATE242008T1
(de)
|
1998-12-23 |
2003-06-15 |
Searle Llc |
Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
|
|
CA2362147A1
(fr)
*
|
1999-02-12 |
2000-08-17 |
Steve A. Kolodziej |
Nouvelles benzothiazepines-1,2 presentant une activite d'inhibition de transport d'acide biliaire ileal et d'absorption de taurocholate
|
|
DE19916108C1
(de)
|
1999-04-09 |
2001-01-11 |
Aventis Pharma Gmbh |
Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
|
|
GB9914745D0
(en)
*
|
1999-06-24 |
1999-08-25 |
Knoll Ag |
Therapeutic agents
|
|
FR2796070B1
(fr)
|
1999-07-06 |
2003-02-21 |
Lipha |
Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
|
|
SE0000772D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
|
JP2003528830A
(ja)
|
2000-03-10 |
2003-09-30 |
ファルマシア・コーポレーション |
テトラヒドロベンゾチエピン類の製造方法
|
|
US7879840B2
(en)
|
2005-08-25 |
2011-02-01 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the RyR receptors
|
|
US8022058B2
(en)
|
2000-05-10 |
2011-09-20 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the RyR receptors
|
|
US7312044B2
(en)
|
2003-03-07 |
2007-12-25 |
The Trustees Of Columbia University In The City Of New York |
Type 1 ryanodine receptor-based methods
|
|
US7718644B2
(en)
|
2004-01-22 |
2010-05-18 |
The Trustees Of Columbia University In The City Of New York |
Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
|
|
US7393652B2
(en)
|
2000-05-10 |
2008-07-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
|
|
US20020183307A1
(en)
*
|
2000-07-26 |
2002-12-05 |
Tremont Samuel J. |
Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
|
|
EG26979A
(en)
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2002053548A1
(fr)
*
|
2000-12-27 |
2002-07-11 |
Banyu Pharmaceutical Co.,Ltd. |
Derives de la benzothiazepine
|
|
GB0121337D0
(en)
*
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121622D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121621D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2003022286A1
(fr)
|
2001-09-08 |
2003-03-20 |
Astrazeneca Ab |
Derives de benzothiazepine et de benzothiadiazepine presentant une activite inhibitrice du transport des acides biliaires ileaux (ibat), destines au traitement de l'hyperlipidemie
|
|
WO2003040127A1
(fr)
|
2001-11-02 |
2003-05-15 |
G.D. Searle Llc |
Composes benzothiepine mono- et di-fluores en tant qu'inhibiteurs du transport d'acides biliaires a co-dependance sodique apicale (asbt) et de reprise de taurocholate
|
|
MXPA04006255A
(es)
|
2002-01-17 |
2004-09-27 |
Pharmacia Corp |
Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
|
|
EP2316469A1
(fr)
|
2002-02-22 |
2011-05-04 |
Shire LLC |
Système de distribution et méthodes de protection et d'administration de dextroamphetamine
|
|
GB0209467D0
(en)
|
2002-04-25 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0213669D0
(en)
|
2002-06-14 |
2002-07-24 |
Astrazeneca Ab |
Chemical compounds
|
|
US7312208B2
(en)
|
2002-08-28 |
2007-12-25 |
Asahi Kasei Pharma Corporation |
Quaternary ammonium compounds
|
|
US7544678B2
(en)
|
2002-11-05 |
2009-06-09 |
The Trustees Of Columbia University In The City Of New York |
Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
|
|
GB0304194D0
(en)
|
2003-02-25 |
2003-03-26 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
|
US8710045B2
(en)
|
2004-01-22 |
2014-04-29 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the ryanodine receptors
|
|
ATE555101T1
(de)
*
|
2004-02-27 |
2012-05-15 |
Asahi Kasei Pharma Corp |
Neue benzothiazepin- und benzothiepinverbindungen
|
|
US7704990B2
(en)
|
2005-08-25 |
2010-04-27 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the RyR receptors
|
|
US9339480B2
(en)
*
|
2008-11-26 |
2016-05-17 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of obesity and diabetes
|
|
JO3131B1
(ar)
*
|
2010-04-27 |
2017-09-20 |
Glaxosmithkline Llc |
مركبات كيميائية
|
|
EP4137137A1
(fr)
|
2010-05-26 |
2023-02-22 |
Satiogen Pharmaceuticals, Inc. |
Inhibiteurs et satiogènes de recyclage d'acide biliaire pour le traitement du diabète, de l'obésité et d'états gastro-intestinaux inflammatoires
|
|
PL3400944T3
(pl)
|
2010-11-04 |
2020-11-16 |
Albireo Ab |
Inhibitory ibat w leczeniu chorób wątroby
|
|
CN105287604B
(zh)
|
2010-11-08 |
2019-07-09 |
阿尔比里奥公司 |
含ibat抑制剂和胆汁酸结合剂的药物组合
|
|
JP2015003861A
(ja)
*
|
2011-10-18 |
2015-01-08 |
株式会社カネカ |
(r)−2−アミノ−2−エチルヘキサノールの製造法
|
|
AU2012328526B2
(en)
|
2011-10-28 |
2017-05-25 |
Shire Human Genetic Therapies, Inc. |
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
|
|
EA029581B1
(ru)
|
2011-10-28 |
2018-04-30 |
ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи |
Применение ингибиторов рециркуляции желчных кислот для лечения холестатического заболевания печени или прурита
|
|
MX2015013196A
(es)
|
2013-03-15 |
2016-04-15 |
Lumena Pharmaceuticals Inc |
Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
|
|
WO2014144650A2
(fr)
|
2013-03-15 |
2014-09-18 |
Lumena Pharmaceuticals, Inc. |
Inhibiteurs du recyclage de l'acide biliaire pour le traitement de l'angiocholite sclérosante primaire et de la maladie inflammatoire de l'intestin
|
|
JO3301B1
(ar)
|
2013-04-26 |
2018-09-16 |
Albireo Ab |
تعديلات بلورية على إيلوبيكسيبات
|
|
WO2015199147A1
(fr)
|
2014-06-25 |
2015-12-30 |
味の素株式会社 |
Préparation pharmaceutique solide, et procédé d'inhibition ou d'atténuation de coloration de celle-ci
|
|
EP3177600B1
(fr)
*
|
2014-08-05 |
2018-05-23 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Synthese des benzothiazepines.
|
|
EP3012252A1
(fr)
|
2014-10-24 |
2016-04-27 |
Ferring BV |
Formes crystallines d'Elobixibat
|
|
CA3011565C
(fr)
|
2016-02-09 |
2024-01-02 |
Albireo Ab |
Formulation orale de cholestyramine et utilisation associee
|
|
WO2017138878A1
(fr)
|
2016-02-09 |
2017-08-17 |
Albireo Ab |
Formulation orale de cholestyramine et utilisation associée
|
|
US10441604B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Cholestyramine pellets and methods for preparation thereof
|
|
US10441605B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US10786529B2
(en)
|
2016-02-09 |
2020-09-29 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
WO2019032026A1
(fr)
|
2017-08-09 |
2019-02-14 |
Albireo Ab |
Granules de cholestyramine, formulations orales de cholestyramine et leur utilisation
|
|
EP3664782B1
(fr)
|
2017-08-09 |
2025-01-29 |
Albireo AB |
Pastilles de cholestyramine, formulations orales de cholestyramine et leur utilisation médicale
|
|
US10793534B2
(en)
|
2018-06-05 |
2020-10-06 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
JP7391048B2
(ja)
|
2018-06-05 |
2023-12-04 |
アルビレオ・アクチボラグ |
ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
|
|
JOP20200299A1
(ar)
|
2018-06-20 |
2020-11-22 |
Albireo Ab |
صيغة صيدلانية لأوديفيكسيبات
|
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
|
US11549878B2
(en)
|
2018-08-09 |
2023-01-10 |
Albireo Ab |
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US10941127B2
(en)
|
2019-02-06 |
2021-03-09 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
US10975045B2
(en)
|
2019-02-06 |
2021-04-13 |
Aibireo AB |
Benzothiazepine compounds and their use as bile acid modulators
|
|
JP7504110B2
(ja)
|
2019-02-06 |
2024-06-21 |
アルビレオ・アクチボラグ |
ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
|
|
WO2020161217A1
(fr)
|
2019-02-06 |
2020-08-13 |
Albireo Ab |
Composés de benzothiadiazépine et leur utilisation en tant que modulateurs d'acide biliaire
|
|
JP2022520121A
(ja)
|
2019-02-12 |
2022-03-28 |
ミルム ファーマシューティカルズ インコーポレイテッド |
胆汁うっ滞を治療する方法
|
|
US11014898B1
(en)
|
2020-12-04 |
2021-05-25 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
|
AR120683A1
(es)
|
2019-12-04 |
2022-03-09 |
Albireo Ab |
Compuestos de benzoti(di)azepina y su uso como ácido biliar
|
|
JP7665620B2
(ja)
|
2019-12-04 |
2025-04-21 |
アルビレオ・アクチボラグ |
ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
|
|
CN114761080B
(zh)
|
2019-12-04 |
2024-07-23 |
阿尔比里奥公司 |
苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
|
TWI877263B
(zh)
|
2019-12-04 |
2025-03-21 |
瑞典商艾爾比瑞歐公司 |
苯并噻二氮呯化合物及其作為膽酸調節劑之用途
|
|
TWI871392B
(zh)
|
2019-12-04 |
2025-02-01 |
瑞典商艾爾比瑞歐公司 |
苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
|
|
AR120679A1
(es)
|
2019-12-04 |
2022-03-09 |
Albireo Ab |
Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
|
|
JP7696898B2
(ja)
|
2019-12-04 |
2025-06-23 |
アルビレオ・アクチボラグ |
ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
|
|
IL293379A
(en)
|
2019-12-04 |
2022-07-01 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
AR120674A1
(es)
|
2019-12-04 |
2022-03-09 |
Albireo Ab |
Compuestos de benzotiazepina y su uso como ácido biliar
|
|
CA3186857A1
(fr)
|
2020-08-03 |
2022-02-10 |
Per-Goran Gillberg |
Composes de benzothia(di)azepine et leur utilisation en tant que modulateurs de l'acide biliaire
|
|
WO2022029101A1
(fr)
|
2020-08-03 |
2022-02-10 |
Albireo Ab |
Composés de benzothia(di)azepine et leur utilisation en tant que modulateurs de l'acide biliaire
|
|
CA3196488A1
(fr)
|
2020-11-12 |
2022-05-19 |
Albireo Ab |
Odevixibat pour le traitement de la cholestase intrahepatique familiale progressive (cifp)
|
|
WO2022101379A1
(fr)
|
2020-11-12 |
2022-05-19 |
Albireo Ab |
Odévixibat pour le traitement de la cholestase intrahépatique familiale progressive (cifp)
|
|
AU2021390172A1
(en)
|
2020-12-04 |
2023-06-22 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
TW202313579A
(zh)
|
2021-06-03 |
2023-04-01 |
瑞典商艾爾比瑞歐公司 |
苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
|
|
US20230398125A1
(en)
|
2022-06-09 |
2023-12-14 |
Albireo Ab |
Treating hepatitis
|
|
EP4551562A1
(fr)
|
2022-07-05 |
2025-05-14 |
Albireo AB |
Composés de benzothia (di) azépine et leur utilisation en tant que modulateurs d'acide biliaire
|
|
AU2023374724A1
(en)
|
2022-11-03 |
2025-05-01 |
Albireo Ab |
Treating alagille syndrome (algs)
|
|
CN120265290A
(zh)
|
2022-12-09 |
2025-07-04 |
阿尔比里奥公司 |
治疗肾脏疾病的asbt抑制剂
|
|
WO2025093760A1
(fr)
|
2023-11-03 |
2025-05-08 |
Albireo Ab |
Traitement de pfic2 avec de l'odévixibat
|
|
WO2025146508A1
(fr)
|
2024-01-05 |
2025-07-10 |
Albireo Ab |
Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs d'acide biliaire
|
|
WO2025146507A1
(fr)
|
2024-01-05 |
2025-07-10 |
Albireo Ab |
Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs d'acide biliaire
|